Ginsenoside Rg3: A Promising Therapeutic Agent for Traumatic Brain Injury

According to the?2017 Commission?on Traumatic Brain Injury?(TBI), TBI remains one of the top three causes of injury-related death and disability up to 2030. There are?50~60 million people suffering from?TBI each year, with annual expenditure of about US$?400 billion?across the world. Among?all common neurological disorders, TBI has the highest incidence and poses a substantial public health burden.

Strikingly, ginsenoside Rg3, a critical active pharmaceutical component extracted from the traditional Chinese medicine ginseng, has been attested to be effective in reducing neuroinflammation and damage in hippocampal neurons?of mice following TBI, showing great therapeutic potential in TBI.

To get more details, please go to: https://www.bontac.com/article/ginsenoside-rg3-a-promising-therapeutic-agent-for-traumatic-brain-injury.html

#ginsenoside Rg3 #traumatic brain injury #BONTAC